Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach (Review)

Binaschi,Monica; Simonelli,Cecilia; Goso,Cristina; Bigioni,Mario; Maggi,Carlo   Alberto

doi:10.3892/etm.2011.192

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach (Review)

Authors:
- Monica Binaschi
- Cecilia Simonelli
- Cristina Goso
- Mario Bigioni
- Carlo Alberto Maggi
View Affiliations

Affiliations: Department of Pharmacology, Menarini Ricerche, Pomezia, Rome, Italy, Clinical Research Menarini Ricerche, Florence, Italy, Department of Pharmacology, Menarini Ricerche, Florence, Italy
Published online on: January 14, 2011 https://doi.org/10.3892/etm.2011.192
Pages: 173-180

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer has the highest mortality rate among gynaecological tumours despite the fact that the majority of patients with advanced disease achieve complete remission after first-line surgery and chemotherapy. Unfortunately, disease recurrence occurs in the majority of patients and second-line treatments are not curative. Clearly, the persistence of dormant and drug-resistant cells after front-line treatments results in the inability to cure the disease. The identification of cancer-initiating cells or cancer stem cells as key players in the development of recurrence has opened up a novel field of research aimed at identifying additional innovative therapeutic approaches. Strategies of maintenance therapy to extend the survival of patients have been studied, but to date no overall survival benefit has been detected. Currently, numerous clinical trials have just been completed or are ongoing involving patients achieving a complete clinical response after first-line chemotherapy in order to evaluate the efficacy of different therapeutic approaches in terms of disease-free survival and overall survival. At the 2010 ASCO meeting, the first positive results of a phase III clinical trial in this setting were presented: bevacizumab (15 mg/kg i.v. every 21 days) added to first-line chemotherapy and continued for an additional 15 cycles was found to prolong progression-free survival of 3.8 months in comparison to 6 cycles of chemotherapy alone or only 6 cycles of chemotherapy plus bevacizumab. In addition, positive results were announced for a second phase III trial testing bevacizumab in the same setting, but at half dose. The final assessment of the overall clinical benefit and the approval of bevacizumab in maintenance therapy by regulatory agencies is expected to be positive, as are the final results of abagovomab phase III trial MIMOSA, another antibody-based therapy tested as a maintenance treatment for advanced ovarian cancer patients. Encouraging preliminary results confirming the safety profile and the immunogenic activity of abagovomab were presented at the last ASCO meeting. The final results are expected to be released in the first half of 2011.

View Figures

View References

1.	Bast RC, Hennessy B and Lills GB: The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Yap TA, Carden CP and Kaye SB: Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 9:167–181. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Menon U, Gentry-Maharaj A, Hallett R, et al: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10:327–340. 2009. View Article : Google Scholar
4.	Visintin I, Feng Z, Longton G, et al: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 14:1065–1072. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Yurkovetsky Z, Skates S, Lomakin A, et al: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 28:2159–2166. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Kulasingam V, Pavlou MP and Diamandis EP: Integrating highthroughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer. 10:371–378. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Paulsen T, Kjaerheim K, Kaern J, Tretli S and Trope C: Improved short-term survival for advanced ovarian, tubal, peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 16:11–17. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Engelen MJ, Kos HE, Willemse PH, et al: Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 106:589–598. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Earle CC, Schrag D, Neville BA, et al: Effect of surgeon speciality on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 98:172–180. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Fung ET: A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem. 56:327–329. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Moore RG, McMeekin DS, Brown AK, et al: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 112:40–46. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D and Burger RA: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 21:3183–3195. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Dean M, Fojo T and Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar
14.	Szotek PP, Pieretti-Vanmarcke R, Masakiatos PT, et al: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullarian inhibiting substance responsiveness. Proc Natl Acad Sci USA. 103:11154–11159. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Alvero AB, Chen R, Fu H, et al: Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. Cell Cycle. 8:158–161. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Bapat SA, Mali AM, Koppikar CB and Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65:3025–3029. 2005.PubMed/NCBI
17.	Zhang S, Balch C, Chan MW, et al: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Baba T, Covery PA, Matsumura N, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133⁺ ovarian cancer cells. Oncogene. 28:209–218. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Moserle L, Indraccolo S, Ghisi M, et al: The side population of ovarian cancer cells is a primary target of INF-α antitumor effects. Cancer Res. 68:5658–5668. 2008.PubMed/NCBI
20.	Hu L, McArthur C and Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Leizer AL, Alvero AB, Fu HH, et al: Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells. Am J Reprod Immunol. Sept. 5–2010.(E-pub ahead of print).
22.	Hall GD, Brown JM, Coleman RE, et al: Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer. 91:621–626. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Widschwendter M, Fiegl H, Egle D, et al: Epigenetic stem cell signature in cancer. Nat Genet. 39:157–158. 2006. View Article : Google Scholar
24.	Jones PA and Baylin SB: The epigenomic of cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Ito K, Bernardi R and Pandolfi PP: A novel signalling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer initiating cell. Curr Opin Genet Dev. 19:51–59. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Park JT, Chen X, Tropè CG, Davidson B, Shih leM and Wang TL: Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 177:1087–1094. 2010. View Article : Google Scholar : PubMed/NCBI
27.	Lis R, Touboul C, Mirshahi P, et al: Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int J Cancer. 128:715–725. 2010. View Article : Google Scholar : PubMed/NCBI
28.	Rothenberg ML, Liu PY, Wilczynski S, et al: Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: A Southwest Oncology Group Trial (SWOG-9326). Gynecol Oncol. 82:317–322. 2001. View Article : Google Scholar
29.	Bertelsen K, Jakobsen A, Stroyer I, et al: A prospective randomized comparison of 6 and 12 courses of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol. 49:30–36. 1993. View Article : Google Scholar
30.	Lambert HE, Rustin GJ, Gregory WM and Nelstrop AE: A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. Ann Oncol. 8:327–333. 1997. View Article : Google Scholar : PubMed/NCBI
31.	Hakes TB, Chalas E, Hoskins WJ, et al: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol. 45:284–289. 1992. View Article : Google Scholar : PubMed/NCBI
32.	Barakat RR, Sabbatini P, Bhaskaran D, et al: Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol. 20:694–698. 2002. View Article : Google Scholar : PubMed/NCBI
33.	Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 21:2460–2465. 2003. View Article : Google Scholar
34.	Perez-Gracia JL and Carrasco EM: Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol. 84:201–209. 2002. View Article : Google Scholar : PubMed/NCBI
35.	Berek J, Taylor P, McGuire W, Mary Smith L, Schultes B and Nicodemus CF: Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 27:418–425. 2009. View Article : Google Scholar : PubMed/NCBI
36.	Ozols RF: Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol. 13:2451–2453. 2003. View Article : Google Scholar : PubMed/NCBI
37.	Wong C, Wellman TL and Lounsbury KM: VEGF and HIF-1α expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol. 91:513–517. 2003.
38.	Yamamoto S, Konishi I, Mandai M, et al: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer. 76:1221–1227. 1997. View Article : Google Scholar : PubMed/NCBI
39.	Brustamann H: Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Gynecol Oncol. 95:16–22. 2004. View Article : Google Scholar : PubMed/NCBI
40.	Kraft A, Weindel K, Ochs A, et al: Vascular endothelial growth factor in the sera and effusion of patients with malignant and non malignant disease. Cancer. 85:178–187. 1999. View Article : Google Scholar : PubMed/NCBI
41.	Mesiana S, Ferrara N and Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascite formation by immunoneutralization. Am J Pathol. 153:1249–1256. 1998. View Article : Google Scholar : PubMed/NCBI
42.	Mabuchi S, Terai Y, Morishige K, et al: Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res. 14:7781–7789. 2008. View Article : Google Scholar : PubMed/NCBI
43.	Burger RA, Sill MW, Monk BJ, Greer BE and Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 25:5165–5171. 2007. View Article : Google Scholar : PubMed/NCBI
44.	Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar
45.	Richardson DL, Backes FJ, Seamon LG, et al: Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 111:461–466. 2008. View Article : Google Scholar : PubMed/NCBI
46.	Kaye SB: Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol. 25:5150–5152. 2007. View Article : Google Scholar : PubMed/NCBI
47.	Pàez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220–231. 2009.PubMed/NCBI
48.	Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
49.	Loges S, Mazzone M, Hohensinner P and Carmeliet P: Silencing or fueling metastasis with VEGF inhibitors: angiogenesis revisited. Cancer Cell. 15:167–170. 2009. View Article : Google Scholar : PubMed/NCBI
50.	Berchuck A, Rodriguez GC, Kamel A, et al: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol. 164:669–674. 1991. View Article : Google Scholar
51.	Morishige K, Kurachi H, Amemiya K, et al: Involvement of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer. Cancer Res. 51:5951–5955. 1991.
52.	Bartlett JM, Langdon SP, Simpson BJ, et al: The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer. 73:301–306. 1996. View Article : Google Scholar : PubMed/NCBI
53.	Gordon AN, Finkler N, Edwards RP, et al: Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer. 15:785–792. 2005. View Article : Google Scholar
54.	Braly P, Nicodemus CF, Chu C, et al: The immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother. 32:54–65. 2009. View Article : Google Scholar
55.	Jerne NK: Towards a network theory of the immune system. Ann Immunol. 125C:373–389. 1974.PubMed/NCBI
56.	Wagner U, Köhler S, Reinartz S, et al: Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res. 7:1154–1162. 2001.
57.	Reinartz S, Köhler S, Schlebusch H, et al: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res. 10:1580–1587. 2004. View Article : Google Scholar : PubMed/NCBI
58.	Pfisterer J, du Bois A, Sehouli J, et al: The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR Ann Oncol. 17:1568–1577. 2006.PubMed/NCBI
59.	Sabbatini P, Dupont J, Aghajanian C, et al: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res. 12:5503–5510. 2006. View Article : Google Scholar : PubMed/NCBI